An international research group led by Beatrix Süß, a professor at TU Darmstadt, has worked out how a newly developed RNA switch recognizes the antibiotic doxycycline and uses it to turn the reading of a gene on or off. The team carried out the work with partners in Germany and Denmark, and the findings appeared in the journal Nature Communications, according to Informationsdienst Wissenschaft.
The switch, known by the short name G12, was built in the laboratory. It is small and, per the same reporting, performs reliably both in yeast and in human cells. The study is described as the first to explain why the switch functions so well, a result that positions doxycycline as a promising foundation for synthetic biology and possibly for gene therapies.
Why it matters
RNA is best known for carrying genetic information, but it can do considerably more. When an RNA molecule folds into complex three-dimensional shapes, it can act as a sensor and a regulator inside a cell.
Riboswitches — RNA-based switches — have existed for billions of years, mainly in bacteria and other microorganisms, where they help cells adjust their metabolism to a changing environment. A natural riboswitch typically recognizes one specific metabolic product. When that molecule binds, the RNA changes shape and thereby influences whether a genetic message is translated into a protein, and thus into a function or trait. In effect, the riboswitch works like a molecular button that tunes gene expression in response to a chemical signal.
Engineered riboswitches apply the same principle to substances that researchers select themselves. Doxycycline has been used for decades against bacterial infections, is well tolerated, and enters cells easily. Those properties make it an ideal signaling molecule: anyone who introduces it to a cell can operate a chosen RNA switch from the outside. In the Nature Communications study, the antibiotic takes on a second role as the chemical trigger that operates G12.
From tetracycline to doxycycline
Many RNA molecules can bind small compounds, but only a few can be converted into effective riboswitches. Binding alone is not enough. The RNA must also translate molecular recognition into a structural change strong enough to affect gene expression. Finding such rare candidates requires screening large RNA libraries, extensive sequencing, and above all functional tests in living cells.
Süß and her colleagues showed back in 2003 that aptamers — short RNA segments that recognize a specific substance with high precision — could be applied to the antibiotic tetracycline and used to regulate protein production in yeast conditionally. That work, published in Nucleic Acids Research, established one of the pioneering platforms for synthetic RNA switches. The new study builds on it and adds another high-performance regulator to the molecular toolbox, this time triggered by doxycycline and described as more effective than the tetracycline-based switch.
What comes next for G12
The team is continuing to investigate the three-dimensional structure of G12 in order to understand its mode of action better. Such insights could help researchers design future RNA switches deliberately rather than discover them by screening.
Together with partners from academia and industry, the group is also exploring how G12 might be adapted for broader uses in synthetic biology, including controlled expression of selected genes in plants.
Another promising direction is combining G12 with self-cleaving RNA enzymes, known as ribozymes. Such hybrid constructs, often called aptazymes, could be designed so that doxycycline determines whether a messenger RNA (mRNA) remains intact or is cut and subsequently degraded. Over the longer term, this principle could offer an additional layer of control and safety for mRNA-based medicines, including vaccines, as well as for gene therapies. An RNA-based emergency brake of this kind might one day make it possible to slow or halt production of a therapeutic protein if unwanted effects arise.
The team acknowledges that these applications are still at an early stage of development but is convinced that G12 can pave the way toward building such safeguard mechanisms in the near future.
